AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

A GSK drug that targets a pathway behind the lung inflammation in chronic obstructive pulmonary disease, or COPD, has won a long-awaited FDA approval, positioning the biologic medicine to reach ...

The procedure is called bronchoscopic lung volume reduction. It involves inserting small valves into the air tubes of the ...

In both adults with and without self-reported COPD, a 6- or 12-week course of cytisinicline helped more daily smokers achieve ...

In May 2025, the FDA approved mepolizumab (Nucala) as a treatment for chronic obstructive pulmonary disease (COPD). Before any drug gets near a pharmacy shelf, it starts with years of basic science ...

Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill is included. Is chronic coughing or shortness of breath holding you back?

Verona Pharma plc has announced the upcoming presentation of ten posters at the American Thoracic Society Conference 2025, highlighting analyses from its Phase 3 ENHANCE studies of Ohtuvayre ...

In one of the priciest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma, which has its U.S. headquarters in Raleigh, for roughly $10 billion.

Verona Pharma's stock soars into record territory after buyout deal with Merck Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of ...

Discover how cell-based therapy is emerging as a promising treatment option for COPD patients. Learn about its benefits, ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...